Vector purification: issues and challenges with currently available technologiesPublished: September 19, 2019
Downstream Bioprocessing Update
Genetically engineered cell therapies are emerging platforms that have the potential to address unmet clinical needs. Several strategies have been developed for inserting a gene of interest into the target cell, including novel direct DNA and RNA delivery methods. However, viral-based vectors have so far remained the primary platform for these key transductions. The increasing number of products being registered for clinical trials in recent years has created a need for viable Good Manufacturing Process (GMP) vector production. Here we focus on challenges and new developments in purifying vector products at scales that are suitable for cell and gene therapy treatments.DOI: 10.18609/cgti.2019.120
Submitted for review: July 27, 2019
Citation: Cell & Gene Therapy Insights 2019; 5(9), 1125-1132.